IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy

PD-1/PD-L1 is an important signaling pathway in the adaptive immune system. The CD47/SIRPα signaling pathway is a crucial “do not eat me” signal for innate immunity. This study evaluated the anti-tumor mechanism of IMM2520 in vitro and in vivo. IMM2520 was generated using the “mab-trap” platform. IM...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Chunmei Yang, Song Li, Dianze Chen, Dandan Liu, Yanan Yang, Huiqin Guo, Nana Sun, Xing Bai, Guanghui Li, Ruliang Zhang, Tianxiang Wang, Li Zhang, Liang Peng, Sijin Liu, Wei Zhang, Gui Zhao, Xiaoping Tu, Wenzhi Tian
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2024-11-01
Цуврал:	Heliyon
Нөхцлүүд:	PD-L1 CD47 Bispecific antibody IMM2520 Immune therapy Antitumor activity
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2405844024158896
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!